Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
The approval was based on data from the MajesTEC-1 study which included 110 adults with relapsed or refractory multiple myeloma who had previously received ≥3 prior therapies.
Diagnosis & Disease Information
British Society of Haematology Issues Updated Guidelines for Irradiated Blood Components
The British Society of Hematology has updated their guidelines on the use of irradiated blood components.
FDA: More Data on Remestemcel-L for Graft Versus Host Disease Needed
In the CRL, the FDA recommended that the Company conduct at least 1 additional randomized, clinical study.
Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
Clonal Hematopoiesis in Hematologic Malignancies, Bone Marrow Failure Syndromes, and Stem Cell Clones
Recent studies have better elucidated the link between clonal hematopoiesis and hematologic malignancies.
First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma
The FDA has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel; Kite Pharma) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Premyelodysplastic Syndrome Blood Kinetics Linked to Survival, Disease Risk
Premyelodysplastic syndrome blood kinetics are linked to both disease risk and overall survival.
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes
The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
Ziextenzo, a Biosimilar to Neulasta, Receives FDA Approval
The FDA has approved Ziextenzo (pegfilgrastim-bmez; Sandoz), a biosimilar to Neulasta.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...